Regenerative Therapy

A new study finds that mobilized peripheral blood stem cells convey no survival advantage over bone marrow transplants when the donor is not an HLA-identical sibling of the recipient. 

Interview at the annual meeting of the American Society of Hematology –  December 2011 

http://www.youtube.com/watch?v=jHfCqV4Xt4s

“Two-year overall survival among 273 patients randomized to receive filgrastim (Neupogen)-mobilized peripheral blood stem cells (PBSC) from an unrelated donor was 51% in an intention-to-treat analysis, compared with 46% of 278 patients randomized to bone-marrow transplants (BMT), also from an unrelated donor”

http://www.oncologyreport.com/news/clinical/single-article/pbsc-transplants-from-unrelated-donors-show-no-survival-advantage/c85ea16df6.html